Labeler · US market

Oryza Pharmaceuticals Inc.

Oryza Pharmaceuticals Inc. is a US drug labeler with US FDA registrations covering 7 drug concepts (7 currently active) across 36 packages.

ACTIVE — US

openFDA · updated weekly

Labeler codes72516

Active drugs7

Registrations21 active / 21

Packages36

Sole supplier of0 drugs

Portfolio7 drugs · US

Every drug concept this labeler has US registrations for, by package count.

Drug	Type	NDCs	Packages	Status
Metoprolol Succinate tablet, extended release	rx	7	17	SUPPLYING
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate tablet	rx	6	6	SUPPLYING
Bupropion Hydrochloride tablet, extended release	rx	2	6	SUPPLYING
Carbamazepine tablet, extended release	rx	2	2	SUPPLYING
Papaverine Hydrochloride injection, solution	rx	1	2	SUPPLYING
Ticagrelor tablet	rx	2	2	SUPPLYING
Oseltamivir Phosphate powder, for suspension	rx	1	1	SUPPLYING

At a glance

TypeLabeler
Labeler codes72516
Filing names1
Drugs (active)7
Drugs (all time)7
US registrations21
Packages36

Recent events

Shortages, recalls, and registration changes across all filing names.

Oct 12, 2022
SHORTAGEDrug shortage: Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Oryza Pharmaceuticals Inc.)
Mar 14, 2022
RECALLRecall (Class II): PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72…

Watch this company

Alerts for recalls, exits, and new registrations.

Facility locations, FDA inspections, and parent-company mapping are on the roadmap. Name variants reported to FDA under different spellings are merged into this profile; figures cover the entity across all its filing names.